Clinical trials: Loiasis
Loiasis
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.
- Trial name
- NCT05085665
- Testing
- Ivermectin
- Where
- Cameroon
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Loiasis
Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
Background: Many people who live in west or central Africa are at risk for infection from a very small worm called Loa loa. This infection is acquired through the bite of a fly. Baby worms called microfilariae live in the blood.
- Trial name
- NCT02644525
- Testing
- Imatinib Mesylate
- Where
- Cameroon
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Loiasis
Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Background: Loa loa is a small worm that infects people in West and Central Africa. It is spread by the bite of a fly. Adult worms live under the skin and can cause swelling in the arms, legs, and face.
- Trial name
- NCT01593722
- Testing
- Diethylcarbamazine, Ivermectin
- Where
- Cameroon
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Loiasis
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood.
- Trial name
- NCT01111305
- Testing
- Reslizumab, Diethylcarbamazine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)